New York, Jan 14, 2026, 17:40 (EST) — After-hours
- ISRG dropped 2.7% following Intuitive’s forecast of 13% to 15% growth in da Vinci procedures by 2026
- Company reported preliminary Q4 revenue of roughly $2.87 billion, accompanied by its outlook
- Attention now turns to the January 22 results for a deeper look at demand, margins, and system placements
Shares of Intuitive Surgical dropped 2.7% to close at $546.76 on Wednesday, after the company projected slower growth in da Vinci procedures for 2026.
Intuitive now expects procedure growth to hit roughly 13% to 15%. CEO Dave Rosa said they were “pleased with our strong performance” following a preliminary Q4 revenue report of $2.87 billion. archive.fast-edgar.com
This procedure range is crucial because it offers the clearest glimpse investors have into demand for surgical robotics. Growth in procedures fuels the ongoing revenue streams — from instruments and accessories to service — rather than just one-off system sales.
This comes as hospitals juggle capital spending with staffing and budget pressures, while Intuitive rolls out its latest da Vinci 5 system to more ORs. Growth slowing down can quickly sour sentiment, even if short-term revenue holds steady.
Quarterly revenue hit $2.866 billion, broken down into $1.658 billion from instruments and accessories, $785.9 million from systems, and $422.0 million from service.
Recurring revenue—which covers instruments, accessories, service, and some lease income—made up 84% of 2025 sales. The installed base closed out 2025 at 11,106 systems.
Intuitive deployed 532 da Vinci systems this quarter, with 303 of those being da Vinci 5 units. Ion placements dropped to 42.
Intuitive released its preliminary revenue and procedure data in a Form 8-K filing with the U.S. Securities and Exchange Commission.
The decline left Intuitive trailing behind several major medtech peers; Medtronic and Stryker both closed up, even as the S&P 500 slipped 0.53%, according to MarketWatch data.
Still, the initial numbers come with a caveat. Intuitive noted these figures haven’t been audited yet and depend on wrapping up year-end closing steps. Procedure volumes could shift if hospitals hold back on buying or if patient demand wanes.
Investors will be tuning in to see how much of next year’s growth hinges on increased utilization compared to new system placements, and whether the drop in Ion placements is just a blip.
Intuitive is set to release its full fourth-quarter results on January 22, a key date as the company will also field questions about its outlook and operating trends.
